Matthew J. Byerly, MD, an Arizona native, has broad expertise in clinical and translational mental health research, which he applies to projects related to suicide prevention and schizophrenia. For 18 years, Dr. Byerly directed the Schizophrenia and Adult Fragile X Research Programs at UT Southwestern Medical Center where he became a leader in research related to medication adherence, having developed the internationally-recognized Brief Adherence Rating Scale (BARS). From 2015-2018, Dr. Byerly steered the Center for Mental Health Research and Recovery at Montana State University where he focused on addressing suicide and mental health challenges in rural communities.
Dr. Byerly has led or co-led more than 45 clinical trials funded by the NIMH, the state of Montana, and industry sponsors. Additionally, he has served on multiple Scientific Advisory Boards including the Food and Drug Administration Psychopharmacologic Drugs Advisory Committee and the NIMH CATIE Trial. As an educator, Dr. Byerly has mentored many clinicians and early psychiatric researchers. For 10 years, he served as an NIMH-funded Psychiatric Research Education Program (PREP) Director and Associate Residency Training Director for Didactics and Research in the Department of Psychiatry at the University of Texas Southwestern Medical Center and received six awards for outstanding teaching.
Dr. Byerly’s research efforts focus on two mental health topics: suicide prevention and medication adherence.
Suicide Prevention: Suicide is a major public health problem in the US and globally. Dr. Byerly has taken a multi-tier approach, collaborating with leading researchers, to prevent suicide among multiple age groups and high-risk populations. His work concentrates on strengthening mental health resiliency among children and adolescents through delivery of universal, school-based preventive interventions, and reducing risk factors such as depression and anxiety among adults, with an emphasis on military veterans. His current projects related to suicide prevention are the following:
Suicide Prevention among Adolescents - Youth Aware of Mental Health (YAM): YAM is a leading universal, school-based suicide prevention intervention for adolescents. Dr. Byerly, in collaboration with Madhukar Trivedi, MD of UT Southwestern Medical Center, recently completed a pilot study evaluating the feasibility and acceptability of YAM adapted for adolescents in the US.
Reducing Suicide Risk Factors in US Veterans - Thrive for Veterans: Thrive is an evidence-based online treatment for depression and anxiety. Dr. Byerly is leading a team (John Greist, MD, Professor Emeritus, University of Wisconsin; Janet Lindow, PhD, UA/SAVAHCS; and Brett Coleman, President Waypoint Health Innovations, Inc.) to adapt Thrive for US military veterans.
Mental Health Resilience/Suicide Prevention among Native American Children - Good Behavior Game (GBG): The GBG is a universal, evidence-based suicide prevention intervention for school-aged children. Dr. Byerly collaborates with Dr. Lindow on an NIH-funded study assessing the feasibility of implementing the GBG in a Native American preschool setting.
Medication Adherence in Individuals with Mental Illness: Dr. Byerly is leading a 10-site clinical trial testing if the BARS can identify people with schizophrenia who are likely to benefit from an adherence intervention.
Lindow JC, Hughes JL, South C, Minjahuddin A, Gutierrez L, Bannister E, Trivedi MH, and Byerly MJ. The Youth Aware of Mental Health (YAM) intervention: impact on help-seeking, mental health knowledge, and stigma in US adolescents. 2020. In press. doi:10.1016/j.jadohealth.2020.01.006.
Lindow JC, Becker MN, Nakonezny PA, and Byerly MJ. Evaluating an Anti-stigma Intervention Combining Personal Account with Musical Performance among Rural Adolescents. J Rural Mental Health, 43(4), 130–137. 10.1037/rmh0000122
Schure MB, Lindow JC, Greist JH, Nakonezny PA, Bailey SJ, Bryan B, and MJ Byerly. A Randomized Controlled Trial of a Fully Automated Internet-Based Cognitive Behavior Therapy Intervention in a Community Population of Adults with Depression Symptoms. J Med Internet Res. 2019 Nov 18;21(11):e14754. doi: 10.2196/14754. PMID: 31738173
Lindow JC, Hughes JL, South C, Gutierrez L, Bannister E, Trivedi MH, and Byerly MJ. Feasibility and acceptability of the Youth Aware of Mental Health (YAM) intervention in US adolescents. Arch Suicide Res, 2019, 4:1-16. 10.1080/13811118.2019.1624667. PMID: 31159674
Sajatovic M, Legacy S, Correll C, Kane J, DiBiasi F, Fitzgerald H, Ross R, Byerly M. Identifying Patients and Clinical Scenarios for the Use of Long-Acting Injectable Antipsychotics– Expert Consensus Survey Part-I. Neuropsychiatr Dis Treat. 2018; 14:1463-1474.
Sajatovic M, Ross R, Legacy S, Byerly M, Kane J, DiBiasi F, Fitzgerald H, Correll C. Initiating/Maintaining Long-Acting Injectable Antipsychotics in Schizophrenia/Schizoaffective or Bipolar Disorder—Expert Consensus Survey Part 2. Neuropsychiatr Dis Treat. 2018; 14:1475-1492.
Hughes JL, Trivedi MH, Byerly MJ, Lindow JC, South C. Feasibility and acceptability of the Youth Aware of Mental Health (YAM) program in the United States: impact on resilience and depressive symptoms. Symposium presentation at American Psychological Association Meeting, San Francisco, CA, 2018.
Byerly MJ, Lindow JC, Hughes JL, South C, Trivedi MH. Feasibility and acceptability of implementing the Youth Aware of Mental Health (YAM) intervention in Native American School Settings. European Symposium on Suicide & Suicidal Behavior, Belgium, 2018
Schure M, Greist J, Nakonezny P, Bailey S, Bryan B, Byerly M. Efficacy of an Online Cognitive Behavior Therapy Program to Reduce Depressive Symptoms: An 8-week Pragmatic Randomized Clinical Trial Among Rural Montanans. American Public Health Association Annual Meeting, San Diego, CA, November, 2018
Wang J, Ethridge J, Mosconi M, White S, Binder D, Pedapati E, Erickson C, Byerly M, Sweeney J. A resting EEG study of neocortical hyperexcitability and altered functional connectivity in fragile X syndrome. J Neurodev Disord (2017) 9:1. (pre-print).
Ethridge LE, White SP, Mosconi MW, Wang J, Pedapati EV, Erickson CA, Byerly MJ, Sweeney JA. Neural synchronization deficits linked to cortical hyper-excitability and auditory hypersensitivity in fragile X syndrome. Mol Autism. 2017 Jun 7; 8:22.
Ethridge, L. E, White, S. P, Mosconi, M. W, Wang, J., Byerly, M. J, & Sweeney, J. A. Reduced habituation of auditory evoked potentials indicated cortical hyper-excitability in Fragile X Syndrome. Translational Psychiatry (2016) 6, e787(pg. 1-8).
Rosenheck RA, Leslie DL, Sint KJ, Lin H, Li Y, McEvoy JP, Byerly MJ, Hamer RM, Swartz MS, Stroup TS. Cost-Effectiveness of Long-Acting Injectable Paliperidone Palmitate Versus Haloperidol Decanoate in Maintenance Treatment of Schizophrenia. Psychiatr Serv. 2016 Oct 1;67(10):1124-1130.
Nakonezny, P.A., Morris, D.W., Greer, T., Byerly, M.J., Carmody, T., Grannemann, B., Bernstein, I.H., and Trivedi, M.H. Evaluation of Anhedonia with the Snaith–Hamilton Pleasure Scale (SHAPS) in adult outpatients with major depressive disorder. J Psychiatr Res 2015; 65:124-30.
Nakonezny, P.A., Mayes, T.L., Byerly, M.J., and Emslie, G.J. Predicting placebo response in adolescents with major depressive disorder: The Adolescent Placebo Impact Composite Score (APICS). J Psychiatric Res 2015; 68:346-53.
Piotrowski N, Byerly, MJ. Assessing Barriers to Use of Specific Pharmacotherapies for Substance Use Disorders in Psychiatric Residents. Proceedings of the American Academy of Addiction Psychiatry; Am J Addict 2015; 24:79–80.
Jha MK, Lambert ES, Beadles BA, Spradling B, Martinez R, Renfro N, Byerly M. A Case of Frontotemporal Dementia Presenting with Treatment-Refractory Psychosis and Extreme Violence: Response to Combination of Clozapine, Medroxyprogesterone, and Sertraline. J Clin Psychopharmacol. 2015 Dec;35(6):732-3.